Caricamento...
A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ
Despite substantial clinical progress with targeted therapies, current antibody-based approaches have limited efficacy at controlling HER2/neu-positive breast cancers, especially in the absence of chemotherapies. Previously, we showed that the combination of IFNγ and anti-HER2/neu antibody synergist...
Salvato in:
| Pubblicato in: | Oncoimmunology |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Taylor & Francis
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5889208/ https://ncbi.nlm.nih.gov/pubmed/29632709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1300739 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|